Please use this identifier to cite or link to this item:
Title: Adaptation of targeted nanocarriers to changing requirements in antimalarial drug delivery.
Authors: Marques, Joana
Valle-Delgado, Juan José
Urbán, Patricia
Baró, Elisabet
Prohens, Rafel
Mayor, Alfredo
Cisteró, Pau
Delves, Michael
Sinden, Robert E
Grandfils, Christian
de Paz, José L
García-Salcedo, José A
Fernàndez-Busquets, Xavier
Keywords: Glycosaminoglycans;Malaria;Nanomedicine;Plasmodium;Targeted drug delivery
metadata.dc.subject.mesh: Animals
Chondroitin Sulfates
Drug Delivery Systems
Issue Date: 5-Oct-2016
Abstract: The adaptation of existing antimalarial nanocarriers to new Plasmodium stages, drugs, targeting molecules, or encapsulating structures is a strategy that can provide new nanotechnology-based, cost-efficient therapies against malaria. We have explored the modification of different liposome prototypes that had been developed in our group for the targeted delivery of antimalarial drugs to Plasmodium-infected red blood cells (pRBCs). These new models include: (i) immunoliposome-mediated release of new lipid-based antimalarials; (ii) liposomes targeted to pRBCs with covalently linked heparin to reduce anticoagulation risks; (iii) adaptation of heparin to pRBC targeting of chitosan nanoparticles; (iv) use of heparin for the targeting of Plasmodium stages in the mosquito vector; and (v) use of the non-anticoagulant glycosaminoglycan chondroitin 4-sulfate as a heparin surrogate for pRBC targeting. The results presented indicate that the tuning of existing nanovessels to new malaria-related targets is a valid low-cost alternative to the de novo development of targeted nanosystems.
metadata.dc.identifier.doi: 10.1016/j.nano.2016.09.010
Appears in Collections:Producción 2020

Files in This Item:
File SizeFormat 
PMC5332526.pdf1,47 MBAdobe PDFView/Open

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons